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Identifying driver genes in cancer remains a crucial
bottleneck in therapeutic development and basic un-
derstanding of the disease. We developed Helios, an
algorithm that integrates genomic data from primary
tumors with data from functional RNAi screens to
pinpointdrivergeneswithin large recurrentlyamplified
regions of DNA. Applying Helios to breast cancer data
identified a set of candidate drivers highly enriched
with knowndrivers (p < 1014). Nine of ten top-scoring
Helios genes are known drivers of breast cancer, and
in vitro validation of 12 candidates predicted byHelios
found ten conferred enhanced anchorage-indepen-
dent growth, demonstrating Helios’s exquisite sensi-
tivity and specificity. We extensively characterized
RSF-1, a driver identified by Helios whose amplifi-
cation correlates with poor prognosis, and found
increased tumorigenesis and metastasis in mouse
models. We have demonstrated a powerful approach
for identifying driver genes and how it can yield impor-
tant insights into cancer.
INTRODUCTION
Cancer genome data collected by projects such as the The Can-
cer Genome Atlas (TCGA) or the International Cancer Genome
Consortium (ICGC) is defining the landscape of genetic alter-
ations that underlie cancer. Tumor cells may harbor thousands
of genetic lesions including point mutations, somatic copy-num-
ber alterations, and translocations that localize to hundreds or
even thousands of genes. However, most affected genes are
so-called passengers and their alteration does not confer any
type of advantage to tumors (Vogelstein et al., 2013). A pivotal
challenge in cancer genomics is to identify the small subset of
altered genes (so-called drivers) that directly contribute to tumor
fitness and progression.
Exome sequencing studies helped identify driver genes (Curtis
et al., 2012; Stephens et al., 2012), however, themajority of pointmutations display low population frequencies, with only a hand-
ful altered in >5% of patients (Stephens et al., 2012). In breast
cancer, only six genes have point mutations in >5% of samples,
and of these, only PIK3CA (36% frequency) is currently targeted
therapeutically (Cancer Genome Atlas Network, 2012). Instead,
the most recurrent genetic lesions in breast cancer are somatic
copy-number alterations (SCNAs), often driven by inactivation
of DNA repair genes such as BRCA1/2. Indeed, HER2, one
of the most therapeutically targeted drivers in breast cancer, is
primarily dysregulated by copy-number amplification.
The ability to discern drivers from copy-number alteration
promises to dramatically expand the set of therapeutic targets
in this disease. However, this potential is crucially hindered by
the difficulty of driver discovery (Yuan et al., 2012). The crux of
the difficulty is that in all but a few instances, these lesions
contain dozens of genes and no previously characterized drivers
(Albertson et al., 2003). A recent study analyzing multiple tumor
types reported that over 70% of 140 recurrently altered regions
did not contain a known oncogene or tumor suppressor (Zack
et al., 2013). As a result, most recent driver discovery efforts
have focused on point mutations, which directly indicate the
target genes by virtue of their precise location (Kandoth et al.,
2013; Lohr et al., 2012; Wong et al., 2011), and less progress
has been made with respect to SCNAs. However, the increased
frequency of recurring SCNAs relative to point mutations (87
SCNA regions versus six mutated genes with >5% population
frequency) (Figure 1A) highlights the need for methods to
pinpoint drivers within these regions.
Genome-wide pooled-RNAi screening is an alternative
approach to driver gene discovery. In these studies, a short
hairpin RNA (shRNA) library is transduced into cancer cell lines
and the growth effect of each individual gene knockdown is
assessed for each cell line (Cheung et al., 2011; Marcotte
et al., 2012; Silva et al., 2008). While such studies can provide
gene-level resolution, they are currently limited by the high de-
gree of noise, the potential for off-target effects of shRNAs and
by the artificiality of the in vitro screening system (Kaelin, 2012).
Moreover, cell-lines are not fully representative of primary tu-
mor biology as these lack tissue structure and microenviron-
ment, which are key to cellular behavior (Bissell and Hines,
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Given the largely orthogonal strengths and weaknesses
of descriptive analysis of primary cancer genomes and in vitro
genome-wide functional screening, we hypothesized that inte-
grating the two data types into a single approach would result
in increased resolution and accuracy for driver gene discovery.
Therefore, we developed Helios (Figure 1B), an algorithm
that incorporates primary tumor SCNA, point mutations, gene
expression, and RNAi screens into a single candidate driver
score. Helios runs in two steps, first identifying regions of focal
SCNAs and then identifying driver genes within each region by
integrating functional screens and other data using a Bayesian
transfer-learning framework.
Helios displayed a remarkable capacity to pinpoint bona fide
cancer drivers when the algorithm was used to analyze the
SCNA landscape of breast cancer. In a systematic evaluation
of Helios’s performance, we selected 12 driver candidates
identified by Helios, based on their frequency of occurrence,
for experimental investigation. We found ten of 12 candidate
genes induced increased anchorage-independent growth
when overexpressed in vitro. Thus, Helios demonstrated an
unprecedented sensitivity and specificity in identifying genes
that promote oncogenic capabilities. Helios doubled the number
of SCNA drivers identified in breast cancer and substantially
increased our understanding of the breast cancer SCNA
landscape.
RESULTS
ISAR Expands the List of Significantly Amplified Regions
in Breast Cancer
The first step for identifying SCNA-drivers is identification of
significantly altered regions. There are multiple algorithms that
successfully perform this task (Mermel et al., 2011; Walter
et al., 2011), GISTIC2 being the most widely used among these.
We noted a number of oncogenes (e.g., BCL2) that were not de-
tected as falling within a significantly altered region byGISTIC2 in
the TCGA breast cancer data (Cancer Genome Atlas Network,
2012). By visual inspection of chromosome 18, we noted that
while BCL2 does not appear significantly amplified based on
its absolute copy-level, its copy number is nevertheless signifi-
cantly higher than the adjacent chromosomal regions (Figure S1
available online). Most SCNA detection algorithms, including
GISTIC2, compute a null distribution across the entire genome
to estimate the significance of alterations. However, the alter-
ation rate can strongly differ across different genomic regions,
due to features such as DNA secondary structure and DNA
hypomethylation (De and Michor, 2011).
Therefore, we developed Identification of Significantly Altered
Regions (ISAR), an algorithm that accounts for local differences
in SCNA rate due to these and other forces. By computing theFigure 1. Helios Integrates Data from Primary Tumor and Functional S
(A) Frequency of alteration in the TCGA breast cancer data of (top) genes with recu
Significant genes and regions were downloaded from the DBroad Genome
(v. 4.2012021700.0.0) and MutSig (v. 4.2011112800.0.0).
(B) A schematic of our pipeline for the identification of candidate driver genes. The
within those regions, it extracts features from genetic, genomic and functional d
See also Figure S1 and Table S1.significance locally, the algorithm is capable of identifying
both global alteration events, as well as subtle events, such as
a focal amplification within largely deleted regions, that would
be missed if the background distribution for the whole genome
were employed (see Experimental Procedures). We applied
ISAR to 785 breast cancer samples (Cancer Genome Atlas
Network, 2012) and identified 83 significantly amplified regions
(see Table S1), compared to the 30 regions originally reported
by the TCGA consortium. ISAR captures all significant regions
captured by GISTIC2 and many additional regions. Among
the new regions, we find many bona fide or likely oncogenes,
including MYB, BCL2, CDK4, ESR1, FGFR2, FGFR3, and
FGFR4. Identified regions contained an average of 14 genes re-
sulting in a total of 1,226 significantly amplified genes across all
83 regions.
Helios: An Integrative Approach to Pinpoint Drivers
Helios seeks to exploit additional properties—e.g., recurrent
domain-specific point mutations or depletion in a lethality shRNA
screen—to implicate likely driver genes targeted by the SCNA.
Helios considers the entire significantly altered region, but prior-
itizes the genes within this region by incorporating cues from
additional genetic and genomic data to estimate the probability
that each gene is a driver (Figure 2A). It is a statistically rigorous
framework for combining multiple signals that might lack power
individually into a single score for the likelihood that each
gene’s amplification specifically increases tumor fitness. Here,
we integrate features derived from exome-sequencing, shRNA
screening, and gene-expression, but due to the flexibility of
our framework, these could readily be removed, modified, or
extended for subsequent studies.
Helios uses a set of features to classify genes as either drivers
or passengers, based on inferencewithin a hierarchical Bayesian
mixture model (see Experimental Procedures; Figure S2).
Standard classification approaches rely on an initial list of exam-
ples—drivers and passengers—to train the model. Unfortu-
nately, the list of known oncogenic drivers is relatively small
and strongly biased toward kinases and extreme phenotypes
that facilitate discovery. Instead, Helios begins with the assump-
tion that a driver gene is more likely to be near the most
frequently amplified segment (defined as peak) of the ISAR re-
gion. This is used to initialize the algorithm by providing an esti-
mated list of drivers to start from. Helios then iterates between
two stages until convergence by (1) learning the parameters to
distinguish passengers and drivers on the basis of their SCNA
profile and on the additional genomic data, and (2) recomputing
the probability that each gene is a driver using the parameters
determined in step 1.
Helios uses a transfer learning approach (Widmer and Ra¨tsch,
2011) whereby drivers with clearer signal (e.g., at the peak ofcreens
rrent point mutations and (bottom) regions of recurrent copy-number alteration.
Data analysis Center, selecting the TCGA pipeline algorithms GISTIC2
method first uses ISAR to identify regions of focal SCNAs. To pinpoint drivers
ata, which are integrated into a single probabilistic score by Helios.
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Figure 2. Helios Features
(A) Diagram of the classic and Helios approach. While the classic approach relies solely on copy number, both to identify significantly altered regions and to
further narrow down those region to a minimal region of maximal alteration, Helios identifies regions in the same fashion, but then integrates features extracted
from different data sources to compute the probability of each gene being a target of the region.
(legend continued on next page)
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their region) are used to extract informative features to improve
performance in cases with less obvious signal. Helios automati-
cally learns the weights of features directly from the data by
leveraging information among features. In each iteration, Helios
learns a better classification of drivers and passengers, which
in turn is used to learn better parameters, until convergence
(see Extended Experimental Procedures). Helios utilizes a
mixture of two copy-number distributions—one for drivers and
one for passengers, thus avoiding the problematic selection of
a hard threshold for defining aberrant regions (Figure 2B). Addi-
tionally, Helios permits final models wheremore than one gene in
a region is identified as a likely driver, or where no probable driver
genes are identified.
Finally, Helios can readily incorporate additional features,
including complex features generated by combinations of multi-
ple data sources. It automatically learns the contribution and
importance of each feature directly from the data, making it
easily extendable and adaptable to other cancer types. For
example, here, we integrate data from functional screens based
on the concept of oncogene addiction (Weinstein and Joe, 2008)
by deriving a composite statistic reflecting the extent to which
shRNA-depletion in a genome-wide screen correlated with
overexpression of the gene at baseline. A similar idea has
recently been used to discover the oncogene HNF1B (Shao
et al., 2013). Our oncogene addiction score allows for both linear
and nonlinear relations between gene expression and lethality
(See Figures 2B–2D; Experimental Procedures). This ability
to combine multiple weaker pieces of evidence from hetero-
geneous data types into a single score enables Helios to effec-
tively pinpoint the driver gene from within the recurrently altered
region.
Helios Identifies Candidate Drivers of Breast Cancer
We used Helios to integrate TCGA data from 785 primary breast
cancer tumors, including DNA copy number, gene expression,
and sequence mutations (Cancer Genome Atlas Network,
2012), with data from 27 breast cancer cell lines including gene
expression, copy number, and shRNA depletion in a genome-
wide shRNA screen (Barretina et al., 2012; Marcotte et al., 2012).
Using stringent criteria, we defined 64 candidate drivers by se-
lecting only the top gene in each region and applying a threshold
of Helios score >0.5 (see Table S2). Some significant SCNA
regions did not contain a high scoring protein-coding gene;
these amplifications potentially target noncoding RNA or other
genomic features. For example, all protein-coding genes were
low scoring in an amplified region containing the known oncomir
mir21 (O’Day and Lal, 2010). While 20% of the regions con-(B) Diagram of the copy-number model of the Helios Algorithm. The classic appr
(GSDist, x axis) to define the peak region (y axis). Helios (bottom) instead calculate
passenger genes (yellow or brown curves respectively).
(C) Our oncogene addiction score uses monotonic regression to measure the as
differentiate the proto-oncogenic state (I) of the driver, which is expressed at w
expression and high dependency on the gene for survival.
(D) Monotonic regression of the shRNA dropout (y axis) based on the gene dosag
(left) and its neighboring gene in the genome (right). (E) Monotonic regression of th
gene for oncogene addiction in the 14q13 region (left) and its neighboring gene
See also Figure S2.tained more than one high scoring gene, we limited our initial
analysis to the highest scoring gene in each region.
To evaluate the sensitivity of our approach, we combined
several publically available resources to create a comprehen-
sive set of breast cancer oncogenes (Beroukhim et al., 2010;
Uniprot Consortium, 2013; Pletscher-Frankild et al., 2014) (Fig-
ure S3; Extended Experimental Procedures). Among the ten
top-scoring Helios genes, nine were included in this set
(FOXA1, PIK3CA, CCND1, CDK4, MYB, ERBB2, IGF1R, BCL2,
and ESR1), while only five of these appear in regions that are sig-
nificant based on GISTIC2. Moreover, the entire list of 64 Helios
candidates was significantly enriched for our compiled set of
breast cancer drivers (16/64, p value < 4 3 1015), a large
improvement over the set of all genes in amplified regions iden-
tified by GISTIC2 (17/452, p value > 103) (Cancer Genome Atlas
Network, 2012) (Figure 3A). The performance of the method was
also compared against two other algorithms, GAIA (Morganella
et al., 2011) and DiNAMIC (Walter et al., 2011), outperforming
both of them (18/768, p value > 103 and 185/10,651, p value
> 103, respectively). This demonstrates the significant improve-
ment of our integrative approach over the state of the art.
Helios’s integration across multiple data sources is key to its
ability to be both specific and sensitive. Sequence mutations
are gene-specific, but only few drivers harbor such mutations
recurrently. SCNAs typically cover a large number of genes,
making it hard to identify the target of the amplification based
on copy number alone. For instance, CDK4 shares exactly the
same copy-number profile with its five closest neighbors, but
the lethality displayed by CDK4 in the shRNA screen raises its
Helios score (Figure 3B). More strikingly, BCL2 is only the sixth
gene in its region in terms of copy-number alteration frequency,
but its dramatic oncogene addiction score raises its Helios score
well above all others in the region (Figure 3C). In many cases
(e.g., EGFR or ADAM15) (Figures 3D and 3E), it is not any single
feature, but a combination of features that identifies the top-
scoring gene in the region. Figure 3F shows how Helios out-
performs the simple use of the data sources independently to
identify drivers. Even if all of the candidates obtained by each
data source are joined together naively, Helios provides signifi-
cantly better sensitivity (15 versus 9 detected driver genes) and
specificity (hypergeometric enrichment p value of driver genes
8.16 3 1014 versus 4.72 3 1011).
Candidate Selection for Systematic In Vitro Validation of
Helios-Predicted Genes
Helios is designed to rank genes within an amplified region
based on their likely driver capacity. Contrary to most prioroach (top) calculates a hard threshold on the delta to the most altered marker
s the probability (y axis) of displaying a GSDist value (x axis) for both driver and
sociation between gene dosage (x axis) and shRNA dropout (y axis), aiming to
ild-type levels, and the oncogenic state (II), which is characterized by high
e (x axis) for the top-scoring gene for oncogene addiction in the 17q12 region
e shRNA dropout (y axis) based on the gene dosage (x axis) for the top-scoring
in the genome (right).
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Figure 3. Helios Analysis of Breast Cancer
(A) A comparison of enrichment for a literature-compiled set of breast cancer drivers between our Helios genes, defined as the top gene in each region with a
score >0.5 and three state of the art methods.
(B)–(E) display the result of the Helios analysis for the 12p14, 18q21, 1q21, and 7p12 regions, respectively. Genes in the ISAR regions are displayed in the x axis
and the Helios score is represented by bars colored proportionally to the contribution of each feature (a logistic regression approximation is employed to
approximate the contribution of each feature). The G score is displayed as a black line.
(F) A comparison between Helios and the results from the analysis of the data sources individually, testing for enrichment based on our literature compiled set of
breast cancer drivers. See Figures S3A–S3D for information about convergence and stability of the results.work that prioritized mostly kinases for experimental validation,
for an unbiased evaluation of Helios, we chose a systematic
score driven approach to validation. To perform an unbiased
and comprehensive assessment, over a wide range of Helios
scores, we used the independent ISAR score >5.5 to select re-
gions and used Helios to pinpoint the most likely driver within
each region. Thus, we sought to assess how often could Helios1466 Cell 159, 1461–1475, December 4, 2014 ª2014 Elsevier Inc.pinpoint the correct driver for each of the 17 most frequently and
significantly amplified regions.
In seven of the 17 regions, the top Helios gene was a bona-fide
breast cancer oncogene (ERBB2, CCND1, ZNF217, MYC, miR-
21, FGFR2, and IGF1R) and these oncogenes scored well above
thenext best scoringgene. For example,MYC’sHelios scorewas
100 times greater than the second best gene in the region
Figure 4. Helios Validations
Results of the systematic in vitro validation of Helios candidates including the selected genes and five genes selected as negative controls (highlighted in gray).
One or more rows is shown for each of the top 17 highest scoring ISAR peaks regardless of whether or not any gene from the region was tested experimentally.
The ‘‘Ratio Next’’ column indicates the ratio between the Helios score of the candidate gene and the score of the next best scoring gene in the region. The
‘‘Validation p value’’ column displays the statistical significance of the change in colony size between the six empty vector controls and the six repeats of the
cDNA overexpressing the candidate driver gene. Error bars represent 23 SD of the replicates of the assay. The validation p value was computed using a right-
tailed unpaired two-sample t test. The ‘‘Supported Driver’’ column indicates if the gene has been positively validated by the in vitro assay or is a known driver
based on previous literature. The rightmost panel shows the box plots of the colony numbers for each gene in the validation experiment, where gray indicates the
control and green the cDNA overexpressing the candidate driver gene. The colony assay was not performed for several genes that we failed to clone (MYO18A,
SKI), or were bona fide drivers at the top of their peak (ERBB2, ZNF217, FGFR2, IGF1R). Additionally, no gene scored above 0.3 in the 17q23 region, suggesting
that the target was another regulatory element, in this case the bona fide onco-microRNA MIR21. The three green boxes highlight amplified regions in which we
confirmed more than one driver. The colony data that supports this figure is available in Figures S4B (candidate drivers) and S4C (negative controls).
See also Table S2.(Figure 4, ‘‘Ratio-next’’ column). Therewas no knownbreast can-
cer oncogene present among ten additional regions, and there-
fore we decided to perform in vitro validation for the top-scoring
Helios genes in each of these regions. Because an amplified re-
gion can harbor more than one oncogene, we selected multiple
genes if more than one scored significantly (4/10 regions). We
failed to clone overexpression vectors for three genes, resulting
in a final selection of 12 predicted oncogenes for validation.
The selected genes encompassed a wide range of functional
roles including chromatin remodeling, transcription factors, cell
surface, cell adhesion proteins, and metabolic enzymes.
One of the hallmarks of transformation that is commonly used
to investigate putative epithelial oncogenes is the ability to pro-
mote attachment-independent growth of a nontransformed cell
line (Hanahan and Weinberg, 2011). This capacity likely reflectsthe cumulative impact ofmultiple signals suchas increased resis-
tance to stress, increased cellular growth rates and changes in
metabolism (Davison et al., 2013). As a result, many driver alter-
ations in cancermay potentially impact attachment-independent
growth through multiple mechanisms. Therefore, we based our
candidate validation strategy on assaying this phenotype.
Experimental In Vitro Validation Confirms Helios-
Predicted Genes
For each of the 12 candidate genes, we evaluated the ability of a
clone of MCF-10A cells (human mammary epithelium) with
intrinsic low attachment-independent growth ability, (see Exper-
imental Procedures) to form colonies in semisolid media when
the putative oncogene was experimentally upregulated. These
cells were transduced with viral vectors overexpressing theCell 159, 1461–1475, December 4, 2014 ª2014 Elsevier Inc. 1467
putative driver and evaluated for growth in soft agar. CCND1 and
MYC were used as positive controls, and for negative controls,
we selected five genes from significantly amplified ISAR regions
(ISAR>5.5) that did not have a highHelios score (score <0.3). The
agar assays for each gene was tested with a minimum of six rep-
licates and statistical significance was evaluated by unpaired
two-sample t test between the six test and six control plates.
Ten of 12 tested genes (C6ORF23, BEND3, YEATS4, RSF-1,
PRKCZ, GNB1, ZNF652, NIT1, PVRL4, and TRPS1) were able
to significantly increase MCF10A anchorage-independent activ-
ity with a p value of 0.005 or below (Figures 4 andS4). None of the
negative controls demonstrated an increase in colony formation.
This provides in vitro evidence that Helios is highly specific in
identifying genes that provide a selective advantage for breast
cancer cells. Note that a negative result for BRF2 (demonstrated
to be an oncogene in lung cancer) (Lockwood et al., 2010) does
not conclusively rule it out as a driver gene, because attachment-
independent growth is not the only hallmark of cancer and the
assays were performed in a single genetic background.
Overall, Helios demonstrated unprecedented accuracy in
identifying genes that promote oncogenic capabilities. Helios
correctly scored 13/14 drivers at the top of their respected region
(93%). Moreover, 10/12 empirically tested genes validated
(83%), thus we identified ten genes that promote tumorigenic
capabilities in breast cancer (including PVRL4 that was recently
published [Pavlova et al., 2013]). Additionally, because the genes
were selected based on the region’s significance, rather than
their Helios score, a wide range of Helios scores were tested
(between 0.36 and 0.79), increasing our confidence in the candi-
dates identified in other regions. Based on this performance, we
expanded our list of likely drivers based on Helios predictions
with more permissive criteria (Table S3).
Importantly, Helios identified multiple high scoring (likelihood
>0.5) genes for over 20% of the regions. Indeed, we validated
three regions with multiple genes and each gene independently
induced colony formation in vitro (Figure 4, green boxes), indi-
cating that an amplicon often targets more than one gene.
In summary, while previously only 7/17 of the most frequently
altered regions in breast cancer harbored a known oncogene,
following our validation 14/17 regions can be assigned a driver
with substantial confidence.
RSF-1 Promotes Colony Growth In Vitro
Among the ten validated candidates, RSF-1 is an especially
compelling putative driver because it is recurrently amplified in
several cancers (Chen et al., 2011; Fang et al., 2011; Li et al.,
2012; Liu et al., 2012; Shih et al., 2005). Additionally, an amplicon
containing RSF-1 was recently associated with a breast cancer
subtype bearing one of the worst clinical prognoses (Curtis
et al., 2012). Although high expression levels of RSF-1 has been
associated with poor prognosis in several malignancies (Hu
et al., 2012; Li et al., 2012; Liu et al., 2012; Sheu et al., 2013), its
involvement in breast cancer pathogenesis has not yet been
explicitly demonstrated. Therefore, we chose to follow-up our
analysis of RSF-1 with further in vitro and in vivo experiments.
We selected four additional mammary epithelial cell lines
nonamplified for RSF-1. The human MCF-10A-Triple Modified
(a MCF-10A variant sensitized to transformation called here1468 Cell 159, 1461–1475, December 4, 2014 ª2014 Elsevier Inc.MCF-10A-TM) (Pires et al., 2013), MDA-MB-415, MDA-MB-
361, and the mouse Comma-ID (C-ID) (Campbell et al., 1988).
We also selected one cell line (MDA-MB-453, human) with ampli-
fied and overexpressed RSF-1 (Figure S5A). Overexpression of
RSF-1 in all nonamplified cell lines increased the ability to form
colonies in semisolid media (Figure 5A). To assay RSF-1 onco-
gene addiction, we selected two doxycycline (Dox) inducible
shRNA-miRs that efficiently silenced RSF-1 and assayed colony
formation of the RSF-1 amplified MDA-MB-453 line. As ex-
pected, silencing of RSF-1 significantly reduced the number of
colonies formed (Figure 5B). To demonstrate that the loss of
tumorigenic potential is not an off-target effect, we restored
RSF1 expression in these cells by overexpressing the RSF1
cDNA (Figure S5C). Restoring RSF1 levels rescued the ability
of MDA-MB-453 to form colonies in agar despite the expression
of RSF1 shRNAs.
RSF-1 Promotes Growth in Xenograft Models
Next, we conducted experiments to assay RSF-1 in vivo. MCF-
10A-TM and C-ID were orthotopically transplanted into the fat
pad of severe combined immunodeficiency (SCID) mice with
and without prior transduction of an RSF-1 overexpression vec-
tor. We then tracked the development of tumors and compared
growth between controls and those overexpressing RSF-1.
MCF-10A cells are not tumorigenic, and overexpression
of RSF-1 did not transform them. While some transplanted
MCF-10A-TM cells remained in the fat pad, these did not
produce tumor. However, MCF-10A-TM overexpressing RSF-1
was able to establish small primary tumor outgrowths (Figures
5C and S5B). C-ID overexpressing RSF-1 cells generated
palpable masses as early as 2 weeks after transplantation—
significantly earlier than control mice, which lacked detectable
tumor burden after 1 month. (p = 0.0001) (Figures 5D and S5B).
Finally, we also transplanted RSF-1 amplified MDA-MB-453
cells and an MDA-MB-453 variant bearing a doxycycline induc-
ible RSF-1-ShRNA into the fat pad of SCIDmice. As expected, in
the absence of Dox, all MDA-MB-453 variants generated tumors
that grew at a comparable rate. However, supplementing the
mice with Dox reduced the tumorigenic growth specifically in
the tumors carrying the RSF-1 shRNA (Figure 5E). This data pro-
vides evidence that RSF-1 can contribute to tumor progression
in vivo and that inhibition of RSF-1 expression can cause tumor
regression.
RSF-1 Promotes Invasion in Xenograft Models
To further characterize the role of RSF-1 in breast cancer, we
analyzed the TCGA gene expression data and identified gene-
expression signatures associated with RSF-1 expression levels
(Akavia et al., 2010; Danussi et al., 2013) (Extended Experimental
Procedures). Genes associated with RSF-1 in this procedure are
putative downstream targets of RSF-1 activity. We performed
gene set enrichment in these signatures using the MSigDB
database (Subramanian et al., 2005) and found enrichment for
gene sets involved in invasion, metastasis, and de-differentiation
(Figures 6A and S6A).
Therefore, we hypothesized that RSF-1 overexpression may
promote metastatic potential in vivo. To test this, we performed
intravenous tail injection of MCF-10A-TM cells expressing a
A B
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Figure 5. High Expression Levels of RSF-1 Promote Tumorigenesis
(A) Overexpression of RSF-1 in multiple cell lines enhances its ability to form colonies in agar.
(B) downregulation of RSF-1 using Dox-inducible shRNAs in a cell line with amplification of the locus (MDA-MB-453) reduced its ability to form colonies in agar.
(C and D) Overexpression of RSF-1 in (C) MCF-10A-TM and (D) CID cells enhanced their tumorigenic potential in vivo. (C) Overexpression of RSF1 in MCF-10A-
TM cells resulted in the formation of small tumor masses demonstrated in hematoxylin and eosin (H&E) images at right compared to control at left. Number of
tumors formed for each model is available in Figure S5B. (D) Overexpression of RSF1 in CID cells increased tumor volume (left) and weight (right) following
orthotopic transplantation in SCID mice.
(E) Silencing of RSF-1 in MDA-MB-453 attenuated its tumorigenic potential when orthotopically transplanted in SCID mice. Error bars represent SD of n = 3 for
in vitro and n = 6–8 for in vivo studies. Animal studies comply with IACUC regulations.luciferase reporter into SCID mice. When cells are injected intra-
venously in the tail of recipient mice, the cells travel through the
circulatory system and are deposited in the lungs, where the
majority of the cells die due to the absence of a supportivemicro-
environment (Yang et al., 2012). Both control and RSF-1 overex-
pressing cells were rapidly cleared and no signal was detected
1 week after the injection. Importantly, after 7 weeks, all the
mice injected with cells overexpressing RSF-1 showed luciferase
signal in the lungs indicating the formation of lung metastases
while luciferase signal was never recovered in mice injected
with control cells (Figure 6B). This demonstrates that RSF-1 over-expression promotes increased invasive capacity in the lungs
and therefore a prometastatic state in breast cancer cells.
In summary,wehaveshown that overexpressionofRSF-1con-
fers increased anchorage-independent growth in vitro and pro-
motes the formation of lung metastases in mouse models. Addi-
tionally, we have identified a transcriptional signature associated
with RSF-1 amplification in primary tumors that was enriched
for genes related to metastasis and invasion. The identification
of RSF-1 as an oncogene that increases metastasic potential
provides an explanation for the steepmortality of a recently iden-
tified molecular subgroup of breast cancer (Curtis et al., 2012).Cell 159, 1461–1475, December 4, 2014 ª2014 Elsevier Inc. 1469
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Figure 6. RSF-1 Alteration Promotes Metastasis
(A) The analysis of the expression changes related to RSF-1 overexpression in basal primary tumors revealed a signature enriched for invasiveness, migration and
dedifferentiation (table at right). The heat map at left shows genes in the signature as rows and samples as columns and the color indicates the relative expression
(green-low and red-high) and demonstrates the tight correlation of the signature genes across patients. Similar results were observed for luminal primary tumors
(Figure S6A). See Figures S6B and S6C for analysis of downregulated genes.
(B) Comparison of lungmetastasis formation in SCIDmice subjected to tail vein injection ofMCF-10A-TM cells expressing a luciferase reporter and either an RSF-
1 overexpression vector or a control vector. H&E of sectioned lungs from mice injected with control and RSF-1 overexpressing cells is also shown. The arrows
indicate the presence of metastatic outgrowths in the lungs. Animal studies comply with IACUC regulations.DISCUSSION
Cancer research has recently been driven by the hope that ther-
apies targeting drivers will be especially effective in tumors
harboring genetic alterations in the target. This approach relies
on the oncogene addiction effect whereby cancer cells become
dependent on the activity of their altered oncogenes, so that in-
hibiting them compromises cellular viability. This ‘‘personalized
medicine’’ is the basis of some of the most effective therapies,
e.g., those targeting ERBB2 amplification in breast cancer (Ash-
worth et al., 2011). The success of these therapies has fueled ef-
forts to catalog the genomic alterations in numerous cancers1470 Cell 159, 1461–1475, December 4, 2014 ª2014 Elsevier Inc.with the hopes of discovering new therapeutically actionable
mutations.
However, even as data from cancer genomes accumulates,
the identification of actionable driver genes remains a crucial lim-
itation to therapeutic development. We see at least two signifi-
cant bottlenecks. First, only a small subset of established driver
genes are druggable given the current pharmalogical state of the
art (Collins and Workman, 2006). Second, even when a driver
is druggable, it may occur in a very small fraction of patients,
limiting its clinical utility. At present, there is an untapped
resource of driver genes in SCNAs that have evaded discovery.
Moreover, due to the high frequency of SCNA events, actionable
drivers can impact more patients (Figure 1A). However, to date,
this possibility has been limited by the difficultly of distinguishing
passengers and drivers in the majority of SCNAs.
Here, we have presented a major advance in addressing this
challenge, using a method that integrates data from primary tu-
mors with functional assays on cell lines to prioritize candidate
drivers. The unparalleled sensitivity and specificity of Helios
enabled us to execute the first reported systematic validation
of an algorithm designed to identify driver genes. Helios’s perfor-
mance was confirmed by a success rate of 10/12 candidates in
an anchorage-independent growth assay, successfully charac-
terizing several regions for which there was no previously impli-
cated driver. Importantly, because we selected the genes for
validation based on their amplification significance (ISAR score),
rather than their Helios score, we expect that this success rate
will extend to additional regions that have equally strong Helios
scores. Moreover, many of these genes are amplified in addi-
tional epithelial cancers (e.g., C6orf203, NIT1, ZNF652) suggest-
ing possible drivers in those cancers as well.
Using Helios, we have significantly expanded the landscape of
high-confidence breast cancer drivers by more than 2-fold (Fig-
ures 7 and S7). Previous analyses of breast cancer cohorts (Ste-
phens et al., 2012; Cancer Genome Atlas Network, 2012) had
identified 15 driver genes occurring in at least 5% of breast can-
cer tumors (both SCNA and sequence mutations). Our analysis
has doubled this number to 29, substantially expanding the
list of potential drug targets. Even more importantly, we have
increased the number of drivers identified in each tumor, thus
raising the possibility that at least one might be actionable in
a given patient. A previous study (Figure 7B, gray boxes) (Ste-
phens et al., 2012) could assign each tumor a median of two
established drivers. Adding the Helios validated genes increases
this number to a median of three drivers per tumor (Figure 7B,
green boxes). Adding all predicted drivers with a high Helios
score further expands this number to a median of five drivers
in each tumor (Figure 7B, yellow boxes). Thus Helios has sub-
stantially expanded the set of high-confidence drivers in breast
cancer.
Helios uses a technique called transfer learning, whereby
drivers with clearer signal (e.g., at the peak of their region) help
learn informative features to improve performance in cases
with less obvious signal. Helios learns the list of candidate
drivers without using any prior list of driver genes and therefore
it does not suffer from any bias. The algorithm uses all data in
its learning process, transferring information across different
genes, as well as between SCNAs and other features, until it
converges into a final ranking of candidate driver genes. By
leveraging information in this fashion, Helios is capable of
learning how to weigh and combine features into a probabilistic
score that represents the likelihood of the gene being the target
of the recurrent alteration. This computational framework is inde-
pendent of the features and tumor type and it can be applied to
analyze additional cancers using a similar or even different set of
features.
Genetic, genomic and functional data on cancers will continue
to accumulate from large-scale projects in the coming years
(Cheung et al., 2011; Cancer Genome Atlas Network, 2008).
Such data sets continue to accelerate drug development andto yield deep insights into oncogenesis. However, they also
create new analytical challenges such as the need to pinpoint
the alterations that promote cancer. Helios can be viewed as
an accurate in silico screen for drivers. As such, it can be applied
to additional cancer types and data types to accelerate the
identification of cancer drivers.
EXPERIMENTAL PROCEDURES
ISAR
ISAR is based on the G score metric, a significance measure of the aberration
for each marker, which was originally defined in GISTIC (Beroukhim et al.,
2007). Specifically, the G score for a marker m is the summation of the copy
number across samples that surpass an aberration threshold q. Given the
copy number for n samples, the G score for a marker m in the case of ampli-
fications is:
GAMPðmÞ=
XN
i = 1
CNðm; iÞ3 ICNðm; iÞ> qAMP; (Equation 1)
where CN(m,i) is the copy number of marker m in sample i and I is the indicator
function.
ISAR uses a local sliding window of constant size that moves along the
chromosome, calculating the null distribution for each window. Once the
distribution has been computed in all windows within a chromosome, each
genomic marker is associated with several overlapping windows. The
algorithm takes a conservative approach by selecting the least significant q
value among the values computed for all overlapping windows containing
the marker (see Extended Experimental Procedures for more detail).
Modeling Copy Number
We aim to model a distribution of SCNA that reflects the differences between
driver and passenger genes, independently of the chromosomal region. How-
ever, in contrast to the subtle differences in SCNA within each altered region,
the distribution of alterations differs dramatically between regions. Indeed, the
median difference in G score between genes in a region is significantly smaller
(172) than the difference for genes across different regions (6,405). Thus,
without appropriate normalization, the G score should not be used to prioritize
drivers across regions. We aim to model whether the gene is among the most
altered genes in its own region (and thereforemore likely to be the driver of that
region) and therefore define ametric that measures the difference in terms of G
score to the highest value in each region. For a single gene g, we define the
GSDist score as:
GSDistðgÞ= max
j˛regionðgÞ
ðGscoreðjÞ GscoreðgÞÞ: (Equation 2)
The most altered gene(s) in a region will have GSDist = 0, while any other gene
will have a positive value that indicates the ‘‘distance’’ to the most frequently
amplified gene in the region. Note that traditional approaches would use a
threshold on this metric to make a hard decision on whether genes in the
altered region are peak genes (Figure 2B). Instead Helios models this metric
using two exponential distributions (one for drivers and one for passengers):
PðSCNAjltÞ= lteltGSDist : (Equation 3)
Driver genes have a GSDist distribution that exponentially decreases from
zero with small variance, whereas passenger genes are modeled by a uniform
distribution, which is approximated by an exponential distribution with large
variance (see Extended Experimental Procedures for more detail).
Features Used in the Helios Algorithm
We use MutSig (Banerji et al., 2012) to compute the statistical significance of
the recurrence of point mutations.Cell 159, 1461–1475, December 4, 2014 ª2014 Elsevier Inc. 1471
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Figure 7. The Landscape of Driver Mutations in Breast Cancer
(A and B) For the driver genes described in Stephens et al. (2012) (gray), Helios validated genes (green), and other Helios genes scoring >5.5 (yellow), we compute
(A) the number of tumors altered (copy number or sequence mutation) for each driver gene and (B) the number of driver genes altered (copy number or sequence
mutation) per tumor. For this figure we consider the 485 primary tumors in TCGA for which both copy number and DNA-Seq were available.
See also Figure S7 and Table S3.Helios uses features extracted from RNA-Seq-based gene expression in
two different ways: (1) to identify genes that are not expressed and therefore
unlikely to be drivers, and (2) we expect the oncogenic activity of an amplified
driver gene to be reflected in the gene’s mRNA dosage (Akavia et al., 2010).1472 Cell 159, 1461–1475, December 4, 2014 ª2014 Elsevier Inc.The oncogene addiction score for a hairpin is defined as the log-likelihood of
the monotonic regression that predicts the lethality based on the gene mRNA.
We use the PAVA algorithm (Brunk, 1955) to estimate the best fit for the regres-
sion (see Extended Experimental Procedures for more detail).
Helios Algorithm
Helios uses a hierarchical Bayesian mixture model to distinguish drivers from
passengers among the genes present in significantly altered regions. The un-
supervised Bayesian algorithm discriminates driver genes (T = 1) by integrating
the copy-number alteration information (SCNA), with cues from different data
sources (X). The hierarchical framework naturally separates these two compo-
nents using the following model:
PðCNAÞ=
X
t˛0;1
PðSCNAjT = tÞPðT = tjXÞ: (Equation 4)
This model separates the modeling of copy number (P(SCNAjT = t)) from other
sources of information (P(T = tjX)), focusing on predicting the observed copy-
number landscape (P(SCNA)). The algorithm iteratively fits a model for each
part: P(SCNAjT = t) and P(T = tjX) and updates the estimations for each
gene (T) taking both parts into account. The algorithm is executed until the
model converges into a stable solution that incorporates all the information
into a single probability score for each gene.
Figure S2A shows the graphical model for Helios, where n genes are classi-
fied by combining the information from different data sources X and SCNA. w
represents the parameters that control the integration of X, while l parameter-
izes the influence of SCNA. In this model, when the values Tn for the genes are
given, the parameters for the different sources (W) and copy number (l) are in-
dependent. This propertymakes it possible to fit themodel efficiently using the
Expectation Maximization (EM) algorithm (see Extended Experimental Proce-
dures for more details).
Data Sets Used for Helios
We used the following public data sets:
Primary tumor data from the TCGA project (Cancer Genome Atlas Network,
2012): copy number Affymetrix 6.0 SNP arrays (n = 785), Illumina HiSeq RNA
sequencing (n = 732), and whole-exome sequencing (n = 507).
Cell line shRNA screens (n = 29) collected by Marcotte et al. (2012).
Cell line data from the Cancer Cell Line Encyclopedia (Barretina et al., 2012)
for the cell lines screened with shRNA: copy number Affymetrix 6.0 SNP arrays
(n = 27) and messenger RNA Affymetrix U133 plus 2.0 arrays (n = 27).
Data Sets Used to Generate Gold Standard Set
To assess performance, a gold standard set of 330 genes was compiled from
the following sources:
The set of known amplified oncogenes from Beroukhim et al. (2010).
The set of genes related to breast cancer according to the University
of Copenhagen DISEASES database (Pletscher-Frankild et al., 2014) with
score >2.5.We filtered out genes categorized as tumor suppressors according
to the Uniprot Consortium (2013).
See Extended Experimental Procedures for more information.
Cell Culture and Reagents
Togenerate cell lines overexpressing a gene, cellswere plated at 60%of conflu-
ence in a 6 well plate and after 24 hr infected with virus expressing the different
plasmids containing the different genes. Media containing virus was replaced in
12 hr for fresh media. Cells were then reinfected for another 12 hr. Cells were
grown in fresh media for 24 hr and selected with the appropriate drug. To
generate MDA-MB 453 cells deficient in RSF1 expression, cells were infected
with virus expressing doxycycline-inducible pTRIPz shRNAs against RSF1.
Then, cells expressing the shRNAs were selected with the puromycin (2 mg/ml).
See Extended Experimental Procedures for cell lines, DNA constructs, and
gene cloning strategy.
Validation of Helios predictions was based on the ability of MCF-10A to form
colonies in semisolid media when the putative oncogene was experimentally
upregulated. Because low passage MCF-10A are very resistant to transfor-
mation, to increase the sensitivity of our assay, we selected a passage with
intrinsic low attachment-independent growth ability (5–15 colonies per 5,000
plated cells) that demonstrated robust higher growth ability when bona-fide
breast oncogenes were overexpressed (Figure S4A).
Colony formation assay in semisolid media was performed in 6 well plates.
First, a layer of 2 ml of 0.6% agar (Fisher 9002-18-0) in regular MCF-10Amediawas placed at the bottom of each well and allowed gelification. Then, a layer of
2 ml of 0.3% agar containing 5,000 cells was seeded on top of the bottom agar
layer and allow gelification. Finally, 1 ml of regular MCF-10Amedia was placed
covering the agar. The colonies were allowed to form for 1 month. After this
period, 2 ml of MTT solution (Sigma M5655) at 0.5 mg/ml was used to stain
the colonies. A minimum of six replicas per gene were plated. To ensure
comparability, transformation assays for each gene are compared to empty-
vector controls performed together on the same day. The number of colonies
was independently evaluated by two researchers. All the different MCF-10A
clones carrying controls and genes of interest were maintained growing expo-
nentially for 48 hr (plates were at 50–70 confluence) before being plated in agar
to homogenize assay conditions.
Tumorigenicity in Mice
Animal maintenance and experiments were performed in accordance with the
animal care guidelines and protocols approved by Columbia University animal
care unit. For Comma-1D cell line, 21-day-old female NODSCID immunocom-
promised mice NOD.CB17-Prkdcs SCID mice (Harlan) mice were injected
with 5 3 105 cells, resuspended in PBS into a fat mammary gland. For MDA-
453 cell line, 8-week-old female NOD SCID immunocompromised mice
NOD.CB17-Prkdcs SCID mice (Harlan) mice where injected with 53 106 cells,
resuspended in 1:2 Matrigel (BD Biosciences) plus normal growth media into a
fat pad mammary gland. Doxycycline was added to drinking water at a final
concentration of 2.0 mg/ml. Tumor growth was monitored twice a week with
calipers at the site of injection. Animals were sacrificed as soon as tumor
size reached 1.5 cm in diameter.
In the experimental metastasis assays, 8-week-old female NOD SCID
immunocompromised NOD.CB17-Prkdcs SCID mice (Harlan) where injected
with 5 3 106 cells, resuspended in PBS, via the tail vein. To measure the
luciferase intensity of injected cells, 2.25 mgml1 luciferin was injected intrave-
nously through the tail and luciferase activity was assessed 5 min after
luciferin injection using a IVIS Spectrum Pre-Clinical In Vivo Imaging System
(IVISSPE; Perkin-Elmer) machine. The presence of established metastases
was confirmed by euthanizing the mice.
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